Wednesday, November 14, 2018 4:44:36 PM
The problem is you are electing to define "end" the way you want to, and ignore all reasonable context.
Nothing says a trial ends with last treatment or even last patient visit, that is your creation.
OTOH, we know a trial is complete when it reaches the defined endpoint (either primary or primary plus all secondaries).
They clearly placed the estimated primary and secondary completion dates in the legally mandated Federal register (clinical trials gov) well before 36 months. There was no ambiguity in those at all. And before you ask, those date are defined as the final primary and secondary, not on a hope for an early IA.
You have seen the protocol that clearly states the endpoints are event driven. Anybody who has followed any clinical trials at knows what that means.
Nothing says a trial ends with last treatment or even last patient visit, that is your creation.
OTOH, we know a trial is complete when it reaches the defined endpoint (either primary or primary plus all secondaries).
They clearly placed the estimated primary and secondary completion dates in the legally mandated Federal register (clinical trials gov) well before 36 months. There was no ambiguity in those at all. And before you ask, those date are defined as the final primary and secondary, not on a hope for an early IA.
You have seen the protocol that clearly states the endpoints are event driven. Anybody who has followed any clinical trials at knows what that means.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
